What laboratory tests are recommended for the diagnosis and management of menopause?

Medical Advisory BoardAll articles are reviewed for accuracy by our Medical Advisory Board
Educational purpose only • Exercise caution as content is pending human review
Article Review Status
Submitted
Under Review
Approved

Last updated: June 20, 2025View editorial policy

Personalize

Help us tailor your experience

Which best describes you? Your choice helps us use language that's most understandable for you.

From the Guidelines

Laboratory tests for diagnosing menopause typically include follicle-stimulating hormone (FSH) and estradiol levels, with FSH levels above 30 mIU/mL and low estradiol levels (below 50 pg/mL) supporting a diagnosis in women over 45 with appropriate symptoms. These tests are most useful in ambiguous cases, as menopause is primarily diagnosed clinically based on amenorrhea for 12 consecutive months 1. Additional recommended tests include:

  • Thyroid function tests (TSH, free T4) to rule out thyroid disorders that can mimic menopausal symptoms
  • A lipid panel to assess cardiovascular risk, which increases after menopause
  • Baseline liver function tests, complete blood count, and mammography for women considering hormone therapy
  • Anti-Müllerian hormone (AMH) testing may help predict the timing of menopause in younger women but is not routinely needed for diagnosis 1. It is essential to interpret these laboratory tests in the context of the patient's age, symptoms, and medical history, as hormone levels can fluctuate significantly during perimenopause, potentially leading to misleading results if relied upon exclusively 1.

From the Research

Laboratory Tests for Menopause

The diagnosis and management of menopause involve various laboratory tests to assess hormonal changes and their effects on the body. Some key tests include:

  • Follicle-stimulating hormone (FSH) measurement: Although FSH levels increase with age, they are not a reliable indicator of menopausal status, as levels can fluctuate greatly during the menopausal transition 2, 3.
  • Oestradiol (E2) measurement: E2 levels may decrease with age, but their measurement is not a definitive diagnostic tool for menopause 2, 3.
  • Inhibin measurement: Inhibin levels decrease with age and are inversely correlated with FSH levels 3.
  • Bone mineral density (BMD) tests: BMD tests, such as dual-energy x-ray absorptiometry, can help assess the risk of osteoporosis in postmenopausal women 4.
  • Body composition analysis: Body composition parameters, such as appendicular lean mass and fat mass, can be associated with low bone mass in postmenopausal women 4.
  • Sex hormone-binding globulin (SHBG) and free estrogen index: These measurements can help assess the risk of low bone mass in postmenopausal women 4.

Limitations of Laboratory Tests

While laboratory tests can provide valuable information, they have limitations in diagnosing and managing menopause. For example:

  • FSH measurement is not a reliable indicator of menopausal status due to fluctuating levels during the menopausal transition 2, 3.
  • Hormone levels, such as E2 and inhibin, can also fluctuate and are not definitive diagnostic tools for menopause 2, 3.
  • BMD tests and body composition analysis can provide information on osteoporosis risk and body composition, but may not directly diagnose menopause 4.

Clinical Applications

Laboratory tests can be used in conjunction with clinical evaluation to diagnose and manage menopause. For example:

  • FSH measurement can be used to support the diagnosis of menopause, but should not be relied upon as the sole diagnostic tool 5.
  • BMD tests and body composition analysis can help identify postmenopausal women at risk of osteoporosis and inform treatment decisions 4.
  • Hormone replacement therapy (HRT) and selective estrogen receptor modulators (SERMs) can be used to manage menopausal symptoms and prevent osteoporosis, but their use should be individualized based on clinical evaluation and laboratory test results 6.

References

Guideline

Guideline Directed Topic Overview

Dr.Oracle Medical Advisory Board & Editors, 2025

Research

The menopause: when it is all over or is it?

The Australian & New Zealand journal of obstetrics & gynaecology, 1994

Research

A new biological carrier for follicle stimulating hormone: an aid for the diagnosis of menopause.

Gynecological endocrinology : the official journal of the International Society of Gynecological Endocrinology, 1987

Research

Selective estrogen modulators in menopause.

Minerva ginecologica, 2013

Professional Medical Disclaimer

This information is intended for healthcare professionals. Any medical decision-making should rely on clinical judgment and independently verified information. The content provided herein does not replace professional discretion and should be considered supplementary to established clinical guidelines. Healthcare providers should verify all information against primary literature and current practice standards before application in patient care. Dr.Oracle assumes no liability for clinical decisions based on this content.

Have a follow-up question?

Our Medical A.I. is used by practicing medical doctors at top research institutions around the world. Ask any follow up question and get world-class guideline-backed answers instantly.